Cancer
We’re investigating the biological basis of many solid and blood borne malignancies, advancing diagnosis, developing and trialing new therapies, and improving all aspects of the management of cancer including palliative care.
Do you have a confirmed advanced solid tumor?
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and cohort expansion study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002 administered alone and in combination with a PD-1 monoclonal antibody in advanced solid tumors.
Do you have muscle-invasive Bladder Cancer?
The trial is testing a potential new treatment for Muscle-invasive Bladder Cancer.
Do you have early breast cancer, and have had complete surgical removal of your tumour?
Evaluating the efficacy and safety of post surgical Giredestrant compared with doctors choice of endocrine therapy (Tamoxifen, Anastrozole, Letrozole or Exemestane) in patients with estrogen receptor−positive, HER2-negative early breast cancer.
Do you have gynaecological cancer with hormone receptor positive disease?
This trial is for people with gynaecological cancers whose tumours are potentially treatable with endocrine treatment.
Do you have Muscle-invasive Bladder Cancer?
The trial is testing a potential new treatment called disitamab vedotin for Muscle-invasive Bladder Cancer.
Do you have Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression?
Do you have metastatic , HER2 negative breast cancer?
The purpose of this study is to evaluate the safety and effectiveness of gedatolisib at treating your cancer when combined with other cancer drugs, compared to the standard of care for people with breast cancer.
Do you have locally advanced or metastatic non-clear cell renal cell carcinoma?
The research project is testing a potential new treatment for nccRCC, called XL092 in a combination with nivolumab.
Do you have advanced ovarian, peritoneal or fallopian tube cancer?
A potential new treatment for advanced ovarian, peritoneal or fallopian tube cancer.
Do you have ovarian, peritoneal or fallopian tube cancer?
The purpose of this study is to test a potential new treatment for ovarian, peritoneal or fallopian tube cancer called ZN-c3-also known as azenosertib.